CKD-841 Pharmacokinetic/Pharmacodynamic Study

Phase 1 Completed 13 enrolled Chong Kun Dang Pharmaceutical Severance Hospital · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

A randomized, open-label, single dose, parallel design phase I clinical trial to investigate the safety and pharmacokinetic/pharmacodynamics of CKD-841 or Leuplin Inj. 3.75mg after subcutaneous injection in postmenopausal female.

Timeline

Start: 2016-04
Primary completion: 2017-07
Completion: 2017-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Leuprolide	Other / unclassified	3.75 mg	Subcutaneous

Indications

No indication recorded.